Comprehensive Bioanalytical Services to support your pharmacokinetic and pharmacodynamic assessment
Admescope provides comprehensive quantitative bioanalytical services (non-GLP) for a full spectrum of drug modalities, including small molecules, peptides, oligonucleotides, antibodies, and antibody-drug conjugates (ADCs). Our capabilities go beyond the test compound analysis, we also determine various biomarkers to support your PK/PD assessment.
While our primary focus is on solving challenging cases through thorough, structure- and matrix-based analytical method development, we also routinely perform analyses via method transfer.
Our bioanalytical services are available as part of full in vivo DMPK packages or as standalone analysis for samples provided by our customers. To facilitate the process, our import permit for biological samples covers a wide range of species, ensuring smooth project execution. For cases requiring a specific permit (e.g., CITES-regulated species), we handle applications with local authorities. We are also happy to assist with shipment logistics when needed.
Our state-of-the-art instrumentation—including LC-MS/MS and LC-HR/MS systems—is selected based on the specific needs of each study. Given the diversity of test compound chemistries and the complexity of biological matrices, we maintain a broad analytical toolkit covering the full range of chromatographic techniques (reverse phase, HILIC, chiral). Sample preparation methods range from simple precipitation to advanced solid-phase extraction combined with chemical derivatization. Besides LC-MS analysis, which is applied for both small molecules and biologics, the analytical capabilities include qPCR and ELISA, and we can support you with bioanalysis of samples containing radiolabeled compounds as well.
Reach out to the team to discuss more!
Frequently Asked Questions
Admescope provides quantitative bioanalysis services to support DMPK, pharmacokinetic, pharmacodynamic, and biomarker studies. Services include analytical method development, method transfer, sample analysis, biomarker quantification, and bioanalysis of radiolabelled compounds.
Admescope supports a broad range of drug modalities, including small molecules, peptides, oligonucleotides, antibodies, and antibody-drug conjugates (ADCs), using analytical approaches tailored to the properties of each compound class.
Yes. Bioanalytical services are available as standalone projects, and Admescope can analyse samples generated by customers or third-party study sites in addition to supporting fully integrated DMPK programmes.
Yes. Admescope routinely develops structure- and matrix-specific analytical methods for challenging compounds and biological matrices. Method development approaches are tailored to the characteristics of the test compound and study requirements.
Yes. In addition to custom method development, Admescope routinely performs analyses using transferred analytical methods, helping clients leverage existing assays while maintaining high-quality bioanalytical support.
Admescope uses a range of analytical technologies including LC-MS/MS, LC-HR/MS, qPCR, ELISA, and analytical approaches for samples containing radiolabelled compounds. Analytical platforms are selected according to the requirements of each study and the characteristics of the test compound and matrix.
Admescope maintains a broad analytical toolkit including reverse phase, HILIC, and chiral chromatography. Sample preparation approaches range from protein precipitation to advanced solid-phase extraction and chemical derivatisation techniques.
Yes. Admescope holds import permits covering a wide range of biological samples and can assist with shipment logistics. Where additional permits are required, such as for CITES-regulated species, Admescope can coordinate applications with local authorities.
